[go: up one dir, main page]

DE69731540D1 - Behandlung von diarrhoe - Google Patents

Behandlung von diarrhoe

Info

Publication number
DE69731540D1
DE69731540D1 DE69731540T DE69731540T DE69731540D1 DE 69731540 D1 DE69731540 D1 DE 69731540D1 DE 69731540 T DE69731540 T DE 69731540T DE 69731540 T DE69731540 T DE 69731540T DE 69731540 D1 DE69731540 D1 DE 69731540D1
Authority
DE
Germany
Prior art keywords
animal
reuteri
patient
cells
diarrhea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69731540T
Other languages
English (en)
Other versions
DE69731540T2 (de
Inventor
A Casas
Bo Mollstam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogaia AB
Original Assignee
Biogaia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia AB filed Critical Biogaia AB
Application granted granted Critical
Publication of DE69731540D1 publication Critical patent/DE69731540D1/de
Publication of DE69731540T2 publication Critical patent/DE69731540T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69731540T 1996-06-05 1997-06-03 Behandlung von diarrhoe Expired - Lifetime DE69731540T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/658,473 US5837238A (en) 1996-06-05 1996-06-05 Treatment of diarrhea
US658473 1996-06-05
PCT/US1997/009626 WO1997046104A1 (en) 1996-06-05 1997-06-03 Treatment of diarrhea

Publications (2)

Publication Number Publication Date
DE69731540D1 true DE69731540D1 (de) 2004-12-16
DE69731540T2 DE69731540T2 (de) 2005-10-27

Family

ID=24641378

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69731540T Expired - Lifetime DE69731540T2 (de) 1996-06-05 1997-06-03 Behandlung von diarrhoe

Country Status (12)

Country Link
US (1) US5837238A (de)
EP (1) EP0923293B1 (de)
JP (2) JP2000512634A (de)
AT (1) ATE281840T1 (de)
AU (1) AU734194B2 (de)
BR (1) BR9710689A (de)
CA (1) CA2257077C (de)
DE (1) DE69731540T2 (de)
ES (1) ES2232869T3 (de)
PL (1) PL189998B1 (de)
PT (1) PT923293E (de)
WO (1) WO1997046104A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100388A (en) * 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
US6399055B1 (en) * 1998-10-27 2002-06-04 Compagnie Gervais Danone Method and composition for treatment of infant diarrhea
NZ513804A (en) 1999-03-11 2001-09-28 Nestle Sa Lactobacillus strains capable of preventing diarrhoea caused by pathogenic bacteria and rota viruses
EP1034788A1 (de) * 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Milchsäure Bakterienstämme zur Verhinderung von Diarrhöe
EP1034787A1 (de) * 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus Stämme die gegen pathogenische Bacteria veranlassende Diarrhöe schutzen
US6283294B1 (en) * 1999-09-01 2001-09-04 Biogaia Biologics Ab Enclosed living cell dispensing tube
AU2001272011A1 (en) * 2000-06-19 2002-01-02 Regents Of The University Of Minnesota Siderophores-producing bifidobacteria thereby and uses thereof
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
KR100437497B1 (ko) * 2001-03-07 2004-06-25 주식회사 프로바이오닉 로타바이러스 및 유해 미생물 억제 활성을 가지는 신규내산성 락토바실러스 루테리 프로바이오-16 및 이를함유하는 생균활성제
US20040071793A1 (en) * 2002-10-05 2004-04-15 Bobrowski Paul J. Oral rehydration methods and compositions
US7105336B2 (en) 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
US20050281756A1 (en) * 2004-06-14 2005-12-22 Eamonn Connolly Use of lactic acid bacteria for decreasing gum bleeding and reducing oral inflammation
US7517681B2 (en) * 2003-01-29 2009-04-14 Biogaia Ab Selection and use of lactic acid bacteria for reducing dental caries and bacteria causing dental caries
US6872565B2 (en) * 2003-01-29 2005-03-29 Biogaia Ab Product containing Lactobacillus reuteri strain ATTC PTA-4965 or PTA-4964 for inhibiting bacteria causing dental caries
US20050106267A1 (en) 2003-10-20 2005-05-19 Framework Therapeutics, Llc Zeolite molecular sieves for the removal of toxins
US7955834B2 (en) 2004-06-03 2011-06-07 Biogaia Ab Method for improved breast milk feeding to reduce the risk of allergy
US20060078546A1 (en) * 2004-10-07 2006-04-13 Anders Zachrisson Use of lactic acid bacteria to reduce sick time
US7344867B2 (en) * 2005-04-15 2008-03-18 Eamonn Connolly Selection and use of lactic acid bacteria for reducing inflammation in mammals
US20060251634A1 (en) * 2005-05-06 2006-11-09 Ho-Jin Kang Method of improving immune function in mammals using lactobacillus strains with certain lipids
US8603460B2 (en) 2006-06-05 2013-12-10 Brogaia AB Method of making a Lactobacillus reuteri with increased acid tolerance
US7374924B2 (en) 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis
EP1997499A1 (de) * 2007-05-31 2008-12-03 Puleva Biotech, S.A. Mikroorganismen aus der Muttermilch, Zusammensetzungen, die diese enthalten und deren Verwendung zur Behandlung von Mastitis
US8617537B2 (en) * 2008-06-10 2013-12-31 Biogaia Ab Controlled activation of the reuterin-production machinery of lactobacillus
US20110014324A1 (en) * 2009-07-10 2011-01-20 Christoffer Lundqvist Product for the storage of freeze-dried lactic acid bacteria mixed with oral rehydration solution
LT3564357T (lt) 2010-02-01 2022-07-11 Rebiotix, Inc. Bakterioterapija, skirta clostridium difficile sukeltam kolitui
US20110293710A1 (en) 2010-02-02 2011-12-01 Delphine Saulnier Immunomodulatory properties of lactobacillus strains
IT1401460B1 (it) * 2010-06-11 2013-07-26 Probiotical Spa "ceppi di batteri probiotici produttori di vitamina b12"
JP2010280664A (ja) * 2010-07-02 2010-12-16 Biogaia Ab ラクトバチルス・リューテリ（Ｌａｃｔｏｂａｃｉｌｌｕｓｒｅｕｔｅｒｉ）株を用いる哺乳類における免疫機能の改善方法
EP3311825A1 (de) 2010-08-04 2018-04-25 Thomas Julius Borody Zusammensetzungen zur darmfloratransplantation und verfahren zur herstellung davon und verwendung davon
EP3610881A1 (de) 2011-03-09 2020-02-19 Regents Of The University Of Minnesota Zusammensetzungen und verfahren zur transplantation von biozönose des kolons
US20130022586A1 (en) 2011-07-21 2013-01-24 James Versalovic Production and use of bacterial histamine
GB201206599D0 (en) 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
WO2013180585A1 (en) * 2012-05-29 2013-12-05 Danuta Kruszewska Nanoproduct comprising lactobacillus reuteri dan080 useful in prophylaxis and medicine, both human and veterinary and medical use of the same
EP2674162A1 (de) * 2012-05-29 2013-12-18 Danuta Kruszewska Nanoprodukt, beinhaltend lactobacillus reuteri dan080, zur verwendung bei der prophylaxe, diagnose sowie bei der medizinischen and veterinärmedizinischen behandlung
EP3375447A1 (de) 2013-06-05 2018-09-19 Rebiotix, Inc. Mikrobiotawiederherstellungstherapie (mrt), zusammensetzungen und verfahren zur herstellung
US10716850B2 (en) 2014-12-31 2020-07-21 Wellin, Inc. Anti-inflammatory factor retentate, method of isolation, and use
KR102561989B1 (ko) 2015-05-14 2023-07-31 핀치 테라퓨틱스 홀딩스 엘엘씨 대변 균무리 이식용 조성물, 및 이의 제조 및 사용 방법, 및 이의 전달을 위한 장치
CN114470009A (zh) 2015-05-22 2022-05-13 亚利桑那大学董事会 用于治疗自闭症谱系障碍及相关症状的方法
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
EP3606541A1 (de) 2017-04-05 2020-02-12 Crestovo Holdings LLC Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit (pd) und verwandten erkrankungen
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
AU2018272048B2 (en) 2017-05-26 2024-04-04 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
JP2020530494A (ja) 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド． 健康な腸バリアを維持及び回復するための組成物及び方法
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
WO2024081219A1 (en) 2022-10-14 2024-04-18 Csp Technologies, Inc. Container and method for storing and stabilizing moisture sensitive products
WO2024102831A2 (en) * 2022-11-09 2024-05-16 The Cleveland Clinic Foundation Modulation of the gut microbiome for enhancement of gut and brain health

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3582180D1 (de) * 1984-02-09 1991-04-25 Royal Children S Hospital Rese Lebender attenuierter menschlicher rotavirus-impfstoff und herstellung desselben.
AU5791586A (en) * 1985-05-29 1986-12-04 Pioneer Hi-Bred International, Inc. Treating gastro-intestinal disease in animals
US5413960A (en) * 1987-05-01 1995-05-09 Biogaia Ab Antibiotic reuterin
ATE145243T1 (de) * 1987-05-01 1996-11-15 Biogaia Biolog Ab Antibiotikum-reuterin
US5480641A (en) * 1990-06-15 1996-01-02 Biogaia Ab Feed additive which consists of whey and Lactobacillus reuteri and a method of delivering Lactobacillus reuteri to the gastrointestinal tract
JPH05292947A (ja) * 1992-04-17 1993-11-09 Sanei Touka Kk ラクトバチルス・アシドフィルスｐｎ−ｒｉ−２−４、それを用いた乳酸菌製剤及びその製造方法
ATE239486T1 (de) * 1995-12-21 2003-05-15 Biogaia Ab Verwendung von lactobacillus reuteri zur hemmung der kryptosporidiosis in säugetieren

Also Published As

Publication number Publication date
JP2000512634A (ja) 2000-09-26
PT923293E (pt) 2005-03-31
DE69731540T2 (de) 2005-10-27
EP0923293A1 (de) 1999-06-23
ES2232869T3 (es) 2005-06-01
CA2257077A1 (en) 1997-12-11
CA2257077C (en) 2008-10-07
AU734194B2 (en) 2001-06-07
PL189998B1 (pl) 2005-10-31
EP0923293B1 (de) 2004-11-10
WO1997046104A1 (en) 1997-12-11
ATE281840T1 (de) 2004-11-15
EP0923293A4 (de) 2001-11-07
PL330324A1 (en) 1999-05-10
JP4861500B2 (ja) 2012-01-25
BR9710689A (pt) 1999-08-17
AU3154897A (en) 1998-01-05
US5837238A (en) 1998-11-17
JP2010265303A (ja) 2010-11-25

Similar Documents

Publication Publication Date Title
ATE281840T1 (de) Behandlung von diarrhoe
ATE63748T1 (de) Enzymwiderstandsfaehige immunomodulatorische peptide.
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
GEP20002146B (en) Therapeutic Peptide Derivatives
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
MX340738B (es) Terapia para deficiencia de a-galactosidasa a.
DE3779149D1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
DE68915834D1 (de) Herstellung von T-Zellen und T-Zellmembranen, verwendbar zur Verhütung und Behandlung von Autoimmunkrankheiten.
DE69434218D1 (de) Photodynamische behandlung von synovium
GEP19981289B (en) Method for Preparing Preserved Medicinal Means Containing Human Protein and Medicinal Means
NZ332720A (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
DE69924483D1 (de) Kombinationstherapie zur behandlung von tumoren
ATE234614T1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
ATE180277T1 (de) Zur behandlung von tumoren und hiv-infektionen nützliches pflanzliches protein
GEP20012511B (en) Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
AU4042795A (en) Treatment of non-small cell lung carcinoma
DE69124382D1 (de) Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
EP0321094A3 (de) Behandlung von Faktor-VIII-Inhibitoren
UA7955A (uk) Спосіб лікування туберкульозу легенів
GEP19981480B (en) Method for Treating Vertebral Column
UA10281C2 (uk) Спосіб отримання речовини для лікування захворювань підшлункової залози

Legal Events

Date Code Title Description
8364 No opposition during term of opposition